Table 1.

Patients enrolled in the nine-country study with treatment success assessed at the end of treatment, and with at least one culture result available during post-treatment follow-up.

Patients characteristics		Total	Successfully treated	With >=1 follow-up culture		P-value
		N	N	n	%
Country						<10–3
	Burkina Faso	34	29	27	93.1
	Burundi	61	56	54	96.4
	Benin	29	25	24	96.0
	DRC	301	242	129	53.3
	CAR	45	36	29	80.6
	Côte d'Ivoire	260	207	100	48.3
	Cameroon	176	149	130	87.2
	Niger	62	48	44	91.7
	Rwanda	38	31	21	67.7
Sex						0.300
	Female	338	275	193	70.2
	Male	668	548	365	66.6
Age group						0.196
	18–24 years	186	153	107	69.9
	25–34 years	351	285	183	64.2
	35–44 years	269	228	157	68.9
	45–54 years	141	117	78	66.7
	55–64 years	37	26	23	88.5
	>=65 years	22	14	10	71.4
HIV status						0.190
	Positive	200	145	105	72.4
	Negative	806	678	453	66.8
BMI						0.208
	<16.0	211	157	107	68.2
	16.0–16.9	132	102	67	65.7
	17.0–18.4	220	180	114	63.3
	18.5–24.4	420	366	258	70.5
	>=25.0	17	14	11	78.6
	Missing	6	4	1	25.0
Extent of lung lesions						0.144
	<50%	331	278	182	65.5
	>=50%	617	500	350	70.0
	Missing	58	500	26	57.8
Category						0.240
	New case	134	109	67	61.5
	Retreatmenta	850	693	475	68.5
	Other	22	21	16	76.2
Total		1006	823	558	67.8

BMI: body mass index in kg/m².

^aIncluding 236 relapses after first-line treatment and 589 failures of first-line treatment.